120 related articles for article (PubMed ID: 12559029)
1. The causes and treatment of reactions to platelet transfusions.
Blumberg N; Phipps RP; Kaufman J; Heal JM
Transfusion; 2003 Feb; 43(2):291-2; author reply 292. PubMed ID: 12559029
[No Abstract] [Full Text] [Related]
2. Cytokines and related molecules, and adverse reactions related to platelet concentrate transfusions.
Cognasse F; Garraud O
Transfus Clin Biol; 2019 Sep; 26(3):144-146. PubMed ID: 31327557
[TBL] [Abstract][Full Text] [Related]
3. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion.
Phipps RP; Kaufman J; Blumberg N
Lancet; 2001 Jun; 357(9273):2023-4. PubMed ID: 11438137
[No Abstract] [Full Text] [Related]
4. Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes.
Refaai MA; Phipps RP; Spinelli SL; Blumberg N
Thromb Res; 2011 Apr; 127(4):287-91. PubMed ID: 21093892
[TBL] [Abstract][Full Text] [Related]
5. Platelet soluble CD40-ligand level is associated with transfusion adverse reactions in a mixed threshold-and-hit model.
Cognasse F; Sut C; Fromont E; Laradi S; Hamzeh-Cognasse H; Garraud O
Blood; 2017 Sep; 130(11):1380-1383. PubMed ID: 28720587
[No Abstract] [Full Text] [Related]
6. The febrile platelet transfusion reaction: a cytokine shower.
Ferrara JL
Transfusion; 1995 Feb; 35(2):89-90. PubMed ID: 7825217
[No Abstract] [Full Text] [Related]
7. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions.
Blumberg N; Gettings KF; Turner C; Heal JM; Phipps RP
Transfusion; 2006 Oct; 46(10):1813-21. PubMed ID: 17002639
[TBL] [Abstract][Full Text] [Related]
8. Platelet transfusion reactions: febrile nonhemolytic reaction or bacterial contamination? Diagnosis, detection, and current preventive modalities.
Sharma AD; Grocott HP
J Cardiothorac Vasc Anesth; 2000 Aug; 14(4):460-6. PubMed ID: 10972618
[No Abstract] [Full Text] [Related]
9. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations.
Klüter H; Bubel S; Kirchner H; Wilhelm D
Transfusion; 1999; 39(11-12):1179-84. PubMed ID: 10604243
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets.
Heddle NM; Blajchman MA; Meyer RM; Lipton JH; Walker IR; Sher GD; Constantini LA; Patterson B; Roberts RS; Thorpe KE; Levine MN
Transfusion; 2002 May; 42(5):556-66. PubMed ID: 12084163
[TBL] [Abstract][Full Text] [Related]
11. ABO-mismatched transfusions are not over-represented in febrile non-haemolytic transfusion reactions to platelets.
Yazer MH; Raval JS; Triulzi DJ; Blumberg N
Vox Sang; 2012 Feb; 102(2):175-7. PubMed ID: 21781126
[TBL] [Abstract][Full Text] [Related]
12. A computerized prediction model of hazardous inflammatory platelet transfusion outcomes.
Nguyen KA; Hamzeh-Cognasse H; Sebban M; Fromont E; Chavarin P; Absi L; Pozzetto B; Cognasse F; Garraud O
PLoS One; 2014; 9(5):e97082. PubMed ID: 24830754
[TBL] [Abstract][Full Text] [Related]
13. Febrile neutropenia contributes to underreporting of potential septic platelet transfusion reactions.
Olsen KE; Sandler SG
Vox Sang; 1996; 70(2):118. PubMed ID: 8801761
[No Abstract] [Full Text] [Related]
14. Febrile reactions after platelet transfusion: the effect of single versus multiple donors.
Chambers LA; Kruskall MS; Pacini DG; Donovan LM
Transfusion; 1990; 30(3):219-21. PubMed ID: 1967118
[TBL] [Abstract][Full Text] [Related]
15. Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets.
Wang RR; Triulzi DJ; Qu L
Am J Clin Pathol; 2012 Aug; 138(2):255-9. PubMed ID: 22904138
[TBL] [Abstract][Full Text] [Related]
16. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
Hamzeh-Cognasse H; Laradi S; Osselaer JC; Cognasse F; Garraud O
Vox Sang; 2015 Feb; 108(2):205-7. PubMed ID: 25334045
[TBL] [Abstract][Full Text] [Related]
17. [Introduction of platelet additive solution in platelet concentrates: towards a decrease of blood transfusion reactions].
Rebibo D; Simonet M; Hauser L
Transfus Clin Biol; 2008 Nov; 15(5):289-93. PubMed ID: 18930424
[TBL] [Abstract][Full Text] [Related]
18. Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction.
Couban S; Carruthers J; Andreou P; Klama LN; Barr R; Kelton JG; Heddle NM
Transfusion; 2002 Jun; 42(6):753-8. PubMed ID: 12147029
[TBL] [Abstract][Full Text] [Related]
19. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
20. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions.
Hamzeh-Cognasse H; Damien P; Nguyen KA; Arthaud CA; Eyraud MA; Chavarin P; Absi L; Osselaer JC; Pozzetto B; Cognasse F; Garraud O
Transfusion; 2014 Mar; 54(3):613-25. PubMed ID: 23944651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
